Subretinal pseudocyst: A novel optical coherence tomography finding in age-related macular degeneration

Eur J Ophthalmol. 2020 May;30(3):NP24-NP26. doi: 10.1177/1120672119846437. Epub 2019 Apr 25.

Abstract

Purpose: To report the presence of a new structural optical coherence tomography finding, namely, subretinal pseudocysts, in a patient affected by age-related macular degeneration.

Methods: Case report including multimodal imaging discussion.

Case report: We report a case of a 77-year-old woman affected by age-related macular degeneration from 7 years. Best corrected visual acuity was counting fingers and 20/40 in the right and left eye, respectively. The left eye was affected by type 1 macular neovascularization treated by 34 intravitreal injections of anti-vascular endothelial growth factor (22 ranibizumab and 12 aflibercept injections). Interestingly, structural optical coherence tomography showed the persistence of a subretinal cystoid space (i.e. 'subretinal pseudocyst') after the last anti-vascular endothelial growth factor treatment, even in absence of other signs of exudation.

Conclusions: Subretinal pseudocysts are a new structural optical coherence tomography entity. We reported for the first time the evidence that pseudocysts may develop in the subretinal space in a case of age-related macular degeneration.

Keywords: Age-related macular degeneration; cystoid macular edema; optical coherence tomography; optical coherence tomography angiography; subretinal pseudocyst.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Choroidal Neovascularization / diagnostic imaging*
  • Choroidal Neovascularization / drug therapy
  • Female
  • Fluorescein Angiography / methods
  • Humans
  • Intravitreal Injections
  • Macular Edema / diagnostic imaging*
  • Macular Edema / drug therapy
  • Multimodal Imaging
  • Ranibizumab / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Retrospective Studies
  • Tomography, Optical Coherence / methods*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology
  • Wet Macular Degeneration / diagnostic imaging*
  • Wet Macular Degeneration / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab